Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults (PANFLUVAC)
Preparing for an Influenza Pandemic: A Phase I Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults
The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated locally and systemically and by using haematological, biochemical and immunological screening tests. The immunogenicity of the H5N1 vaccine will be assessed through the induction of local and systemic antibody and cellular immune responses. In a pandemic situation, an important aspect is the rapidity of the immune response to the H5N1 vaccine so the detailed kinetics of the immune response will be investigated. The capacity of the vaccine to elicit long lasting immunity and cross reactive immunity to H5 viruses will also be evaluated. Furthermore, the quality of the immune response induced by the vaccine will be studied. The vaccine will be administered as twice the normal human dose (30μg HA) with and without adjuvant, and in a dose sparing manor of half (7.5μg HA) and one tenth (1.5μg HA) of the normal human dose with adjuvant. Sixty subjects will receive two doses of virosomal H5N1 influenza vaccine (separated by 21 ± 4 days) by intramuscular injection into the deltoid muscle. Escalating doses will be separated by a period of one week. Four groups each containing 15 subjects will receive two doses of the pandemic virosomal A/H5N1 influenza vaccine containing:
Group 1 30µg HA IM, Group 2 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 3 7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 4 30µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM.
연구 개요
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Bergen, 노르웨이, N-5021
- Haukeland Univeristy Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy volunteers (as concluded from the medical history, physical examination, and clinical judgment) aged 19 to 50 years old
- Females using a reliable method of contraception (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy test will be required before administration of each dose of vaccine
- Signed informed consent
- Subjects able to understand and comply with the study protocol and complete the Adverse Event Form
- Subjects able to attend the scheduled visits
- Subjects with normal pre-screening values. If a subjects prescreening samples lie outside the reference values he/she will only be included in the study based upon the medical evaluation of the clinical investigator
Exclusion Criteria:
- Persons with a history of anaphylaxis or serious reactions to any vaccine
- Persons with known hypersensitivity to any of the vaccine components
- Persons who have had a temperature >38oC during the previous 72 hours
- Persons who have had an acute respiratory infection during the last 7 days
- Women who are pregnant or breast-feeding
- Persons with chronic illness at any stage that could interfere with trial conduct or compliance
- Persons who have received blood products or immunoglobulins parenterally during the previous 3 months
- Persons who have been vaccinated with any vaccine during the 4 weeks preceding the first trial vaccination
- Persons with known or suspected immunosuppressive disease or who use systemic immunosuppressive drugs
- Persons taking immunostimulant therapy
- Persons involved in another clinical trial during the last month.
- Suspected non-compliance
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: 1
30µg HA vaccine Intramuscularly administered
|
Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 |
|
활성 비교기: 2
1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
|
Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 |
|
활성 비교기: 3
7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
|
Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 |
|
활성 비교기: 4
30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
|
Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Solicted Adverse Events
기간: three months
|
The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant.
|
three months
|
|
Adverse Events
기간: 42 days
|
42 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine
기간: one year
|
Number of participants with haemagglutination inhibition tigers >= 32 at the long term time point (1 year post vaccination).
|
one year
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Haakon Sjursen, MD, Haukeland Univeristy Hospital
간행물 및 유용한 링크
일반 간행물
- Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis. 2012 Jul 15;206(2):158-66. doi: 10.1093/infdis/jis330. Epub 2012 May 2.
- Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nostbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine. 2011 Oct 19;29(45):8049-59. doi: 10.1016/j.vaccine.2011.08.042. Epub 2011 Aug 22.
- Pedersen GK, Sjursen H, Nostbakken JK, Jul-Larsen A, Hoschler K, Cox RJ. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother. 2014;10(8):2408-16. doi: 10.4161/hv.29583.
- Pedersen GK, Hoschler K, Oie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nostbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014 Jul 31;32(35):4550-4557. doi: 10.1016/j.vaccine.2014.06.009. Epub 2014 Jun 18.
- Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets. PLoS One. 2015 Jul 6;10(7):e0131652. doi: 10.1371/journal.pone.0131652. eCollection 2015.
- Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- PANFLUVAC-2008, Version 2
- EU PANFLUVAC 44115
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Influenza vaccine에 대한 임상 시험
-
Sanofi Pasteur, a Sanofi Company종료됨인플루엔자(건강한 자원봉사자)핀란드
-
Johns Hopkins UniversityMerck Sharp & Dohme LLC완전한
-
The Second Affiliated Hospital of Chongqing Medical...모병